Macquarie Group LTD Fate Therapeutics Inc Transaction History

Macquarie Group LTD

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$21.04 - $36.06 $24,301 - $41,649	-1,155 Reduced 64.49%	636 $40,000
Q1 2022 May 16, 2022	SELL	$29.67 - $60.28 $842,390 - $1.71 Million	-28,392 Reduced 94.07%	1,791 $69,000
Q4 2021 Feb 11, 2022	BUY	$47.84 - $64.34 $35,258 - $47,418	737 Added 2.5%	30,183 $1.77 Million
Q3 2021 Nov 12, 2021	SELL	$59.27 - $95.73 $1.98 Million - $3.2 Million	-33,461 Reduced 53.19%	29,446 $1.75 Million
Q2 2021 Aug 13, 2021	SELL	$67.25 - $92.52 $61,802 - $85,025	-919 Reduced 1.44%	62,907 $5.46 Million
Q1 2021 May 14, 2021	SELL	$72.16 - $117.4 $812,738 - $1.32 Million	-11,263 Reduced 15.0%	63,826 $5.26 Million
Q4 2020 Feb 16, 2021	BUY	$38.09 - $100.95 $242,861 - $643,657	6,376 Added 9.28%	75,089 $6.83 Million
Q3 2020 Nov 13, 2020	SELL	$30.41 - $40.5 $62,735 - $83,551	-2,063 Reduced 2.91%	68,713 $2.75 Million
Q2 2020 Aug 11, 2020	BUY	$20.21 - $35.23 $1.43 Million - $2.49 Million	70,776 New	70,776 $2.43 Million
Q1 2019 May 15, 2019	SELL	$13.15 - $18.71 $9,205 - $13,097	-700 Closed	0 $0
Q4 2018 Feb 15, 2019	SELL	$11.48 - $16.98 $2,296 - $3,396	-200 Reduced 22.22%	700 $9,000
Q3 2018 Nov 15, 2018	SELL	$8.75 - $16.29 $21,000 - $39,096	-2,400 Reduced 72.73%	900 $15,000
Q2 2018 Aug 14, 2018	BUY	$9.16 - $13.48 $30,228 - $44,484	3,300 New	3,300 $37,000
Q1 2018 May 11, 2018	SELL	$6.3 - $13.77 $11,340 - $24,786	-1,800 Closed	0 $0
Q4 2017 Feb 15, 2018	BUY	$3.94 - $6.64 $7,092 - $11,952	1,800	1,800 $11,000

177

113M

53.7K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $126M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Macquarie Group LTD, based on Form 13F filings with the SEC.

Stay updated on Macquarie Group LTD with notifications on news.